GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bolt Biotherapeutics
Bolt Biotherapeutics, an oncology biotech, shares reflect the potential of its innovative platform for creating "immune stimulants." The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Bolt Biotherapeutics is an oncology company developing a new class of immunotherapy—Boltbody™ stimulating antibodies—that activate the immune system directly in tumors. We've categorized the company under "Pharma: Immunology." The chart below shows the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Bolt Biotherapeutics is an oncology company developing a new class of immunotherapeutic drugs that activate innate immunity to fight cancer. Its scientific approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Bolt compares to it.
Change in the price of a company, segment, and market as a whole per day
BOLT - Daily change in the company's share price Bolt Biotherapeutics
Bolt Biotherapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immuno-oncology drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Bolt Biotherapeutics develops immuno-oncology drugs, placing it in a highly volatile sector. The chart below shows the average daily "nervousness" in this industry. It serves as a benchmark for assessing the extent to which the risks embedded in BOLT shares are typical for biotech.
Daily change in the price of a broad market stock, index - GURU.Markets
Bolt Biotherapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex landscape of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bolt Biotherapeutics
For Bolt Biotherapeutics, the year-over-year performance is a story about its unique immunostimulatory antibody platform (ISAC). Its 12-month market cap is entirely dependent on early clinical trial data. Positive results could confirm the potential of its approach to transforming "cold" tumors into "hot" ones, attracting major partners.
Annual dynamics of market capitalization of the market segment - Pharma immune
Bolt Biotherapeutics, Inc. is a clinical-stage biotech company developing a new class of cancer immunotherapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bolt Biotherapeutics is a company at the forefront of immuno-oncology, and its shares are driven by lab news. Its year-over-year performance relative to the market isn't about economics, but rather about hope for a revolution in cancer treatment. Success in trials could boost the stock, demonstrating a complete disconnect from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage immuno-oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its ISAC platform, presented at conferences, is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of immuno-oncology therapeutics known as immunostimulatory antibody conjugates (ISACs). The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its cutting-edge scientific platform in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bolt Biotherapeutics is an immuno-oncology company whose stock is immersed in the world of biotech news. Its dynamics are driven by successes in preclinical and clinical trials. The chart shows that the company's monthly fluctuations barely correlate with the overall market, but are instead a reaction to scientific developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bolt Biotherapeutics
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs. Its weekly stock price performance is a speculative bet on the success of its cutting-edge scientific platform, where clinical data is the primary driver.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Bolt Biotherapeutics develops immuno-oncology drugs. This chart is a tool for assessing how clinical trial news impacts the stock in the short term compared to the overall sector trend. Is the company's volatility a personal story?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bolt Biotherapeutics is another biotech company whose shares exist in their own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, moving along its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
BOLT - Market capitalization of the company Bolt Biotherapeutics
Bolt Biotherapeutics's chart is a bet on the next generation of immuno-oncology. The company's market cap reflects investors' faith in its "immunostimulating antibody conjugate" platform, which is designed to transform "cold" tumors into "hot" ones, susceptible to attack by the immune system.
BOLT - Share of the company's market capitalization Bolt Biotherapeutics within the market segment - Pharma immune
Bolt Biotherapeutics is a biopharmaceutical company developing a new class of immuno-oncology drugs called immune-stimulating antibody conjugates (ISACs). Within the immune-pharma segment, its market capitalization reflects the potential of this innovative platform. The company's market capitalization reflects its bet that its technology can effectively "train" the immune system to attack cancer.
Market capitalization of the market segment - Pharma immune
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs. How big is this arena? The chart below shows the pulse of the entire immuno-pharmaceutical sector. Its high volatility reflects both the enormous hopes for this new generation of cancer drugs and the high risk of clinical failure.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Bolt Biotherapeutics chart is a visualization of a cutting-edge approach in immuno-oncology. The company's market cap is based on its "immune stimulators on a leash" (ISAC) platform, which activates immunity directly within the tumor. It's a chart fraught with scientific risk, but with the potential to transform cancer treatment.
Book value capitalization of the company, segment and market as a whole
BOLT - Book value capitalization of the company Bolt Biotherapeutics
Bolt Biotherapeutics, an immuno-oncology company, derives its book value from its physical foundation: laboratories, rights to the ISAC technology platform, and significant financial reserves for R&D. The chart below shows how the company built this physical foundation to develop a new class of drugs.
BOLT - Share of the company's book capitalization Bolt Biotherapeutics within the market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company. Its main assets are its own GMP manufacturing facilities and laboratories for creating its unique stimulating antibodies. This complex is the physical heart of its technology. The chart shows the share of this advanced biotech infrastructure the company controls.
Market segment balance sheet capitalization - Pharma immune
Bolt Biotherapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Bolt focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Bolt Biotherapeutics' assets are not drugs, but a scientific platform for creating "Bolt-powered immune stimulants," which deliver immunostimulants directly to tumors, essentially "bolting" them with antibodies. Its book value reflects its scientific foundation.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bolt Biotherapeutics
Bolt Biotherapeutics is an oncology company developing "immune-stimulating antibody-based therapeutics" (ISACs). Its value lies in this new platform. The chart shows how the market views its scientific approach and early clinical trial data.
Market to book capitalization ratio in a market segment - Pharma immune
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs. Its valuation is based on its unique ISAC platform. The chart demonstrates investor appreciation for its cutting-edge scientific approach to cancer treatment.
Market to book capitalization ratio for the market as a whole
Bolt Biotherapeutics is an immuno-oncology company. Its market capitalization reflects investor faith in its scientific platform for fighting cancer. This chart demonstrates how valuation in cutting-edge biotech is a bet on a future where intangible assets (IP) are valued disproportionately higher than tangible ones.
Debts of the company, segment and market as a whole
BOLT - Company debts Bolt Biotherapeutics
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs. This is a cutting-edge scientific field that requires significant investment in research and clinical trials. This chart shows how the company is raising significant capital to fund its innovative, but very expensive, scientific platform.
Market segment debts - Pharma immune
Bolt Biotherapeutics is a clinical-stage oncology company developing a new class of immunotherapy. Its future depends on the results of clinical trials. This chart shows its cash reserves and how long it can fund its expensive research without raising new capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bolt Biotherapeutics
Bolt Biotherapeutics is another clinical-stage immuno-oncology company. This chart shows its financial structure. In this highly competitive field, which requires massive investment, debt is an unaffordable luxury. Equity financing is essential to sustain the long research journey.
Market segment debt to market segment book capitalization - Pharma immune
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs that activate the innate immune system to fight cancer. The chart shows the overall debt load in the sector, which helps understand how the company finances its cutting-edge, yet highly risky and expensive, research.
Debt to book value of all companies in the market
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing a new class of drugs to stimulate the immune system against cancer. This chart, reflecting the debt of an established economy, emphasizes that Bolt's funding is a venture bet on the future of medicine, entirely dependent on research results and investor support.
P/E of the company, segment and market as a whole
P/E - Bolt Biotherapeutics
For Bolt Biotherapeutics, an immuno-oncology company, the P/E ratio is not applicable. It has no profit, and its valuation on this chart is arbitrary. It's a speculative bet that its unique approach to "training" the immune system to fight cancer will prove safe and effective in clinical trials.
P/E of the market segment - Pharma immune
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing a new class of therapeutics that combine the precision of antibodies with the power of innate immunity. This chart shows the average valuation for the sector, helping to understand how the market values this cutting-edge scientific platform.
P/E of the market as a whole
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs. Its valuation is a pure bet on the success of its scientific platform. It has no connection to the general economic cycles depicted by this chart. Bolt's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bolt Biotherapeutics
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs called Boltbody ISAC, which activate the innate immune system to fight cancer. This graph reflects the expectations for its innovative platform. The valuation is based on the potential of this technology for the treatment of solid tumors.
%20P%2FE%20Bolt%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bolt-Biotherapeutics&v=1772638857355 "Chart of the company's future (projected) P/E Bolt Biotherapeutics")
Future (projected) P/E of the market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs that activate innate immunity to fight cancer. Its valuation relative to other biotechs reflects investors' opinions on its innovative platform, betting that its technology will prove effective against tumors resistant to other therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772638857356 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs that stimulate innate immunity to fight cancer. This is cutting-edge scientific research. This chart shows the overall risk appetite of investors. For biotechs with innovative platforms like Bolt, a positive market environment is important for raising capital for long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772638857358 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bolt Biotherapeutics
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs—immune-stimulating antibody conjugates (ISACs). The financial performance shown here reflects the clinical trial costs of this cutting-edge and complex cancer treatment technology.
Profit of companies in the market segment - Pharma immune
Bolt Biotherapeutics is another immuno-oncology company developing a new class of drugs that activate innate immunity. This chart reflects the financial health of the immune therapy sector, demonstrating how this cutting-edge field of oncology remains financially viable despite the enormous R&D costs.
Overall market profit
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs. This is cutting-edge science. Like other clinical-stage biotechs, BOLT is only concerned with research results. The economic cycles reflected in this chart do not affect the need for cancer treatments or the scientific process.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bolt Biotherapeutics
Bolt Biotherapeutics is a biotech company developing a new class of immuno-oncology drugs. Its future revenue projections are a long-term bet on the success of its scientific platform. This chart shows how analysts assess the potential of its innovative approach to stimulating the immune system to fight cancer.
%20profit%20of%20the%20company%20Bolt%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bolt-Biotherapeutics&v=1772638857491 "Graph of future (projected) profit of the company Bolt Biotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs called immune-stimulating antibody conjugates (ISACs). Their goal is to turn "cold" tumors into "hot" ones. This chart shows the outlook for immunopharmaceuticals. It illustrates the high hopes for scientific breakthroughs that could expand the application of immunotherapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772638857502 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
For Bolt Biotherapeutics, a company working in the cutting-edge field of immuno-oncology, this chart is an indicator of the investment climate. Expectations of economic growth and risk appetite are driving an influx of capital into biotech, which is necessary for conducting lengthy and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772638857518 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bolt Biotherapeutics
Bolt Biotherapeutics is developing a new class of immuno-oncology therapies. This metric, without revenue, is a pure measure of expectations. Investors evaluate scientific potential and potential future commercial success.
P/S market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs called immunostimulatory antibody conjugates (ISACs). This chart shows the average valuation in the immunopharmaceutical sector. It reflects investor confidence in the potential of Bolt's innovative platform to transform "cold" tumors into "hot" ones.
P/S of the market as a whole
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing a new class of drugs called immune-stimulating, tumor-targeted chemotherapy (ISAC). The company's valuation is based on the potential of this cutting-edge technology. This chart illustrates the market premium for breakthrough scientific approaches in the fight against cancer.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bolt Biotherapeutics
Bolt Biotherapeutics develops immune-stimulating antibodies for cancer treatment. The company's valuation is based on the future potential of its Boltbody ISAC platform. The chart demonstrates investors' belief that its innovative approach to immunotherapy will lead to the development of effective drugs.
%20P%2FS%20Bolt%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bolt-Biotherapeutics&v=1772638857562 "The graph of the company's future (projected) P/S Bolt Biotherapeutics")
Future (projected) P/S of the market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs called immunostimulatory antibody conjugates (ISACs). These deliver an immunostimulatory agent directly to the tumor. This chart shows how investors view the potential of this innovative technology platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772638857575 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
This illustrates the general sentiment of investors in immuno-oncology. For Bolt Biotherapeutics, a company developing drugs that activate innate immunity against cancer, this demonstrates faith in new approaches. Market optimism allows it to fund the development of complex "immune stimulators" targeting tumor cells.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772638857589 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bolt Biotherapeutics
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs—immunostimulating antibody conjugates—that activate the innate immune system to fight cancer. This chart reflects partnership revenue. Future revenue is dependent on the success of clinical trials of this innovative platform.
Sales of companies in the market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs called immune-stimulating antibody conjugates (ISACs). This chart shows the growth of the immunopharmacology market. Bolt's technology aims to transform "cold" tumors into "hot" ones, making them vulnerable to the immune system.
Overall market sales
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs that stimulate the immune system to fight cancer. Its market capitalization depends on progress in clinical trials. This overall economic activity schedule influences the investment climate in the biotech sector, determining the availability of financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bolt Biotherapeutics
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs—immunostimulating antibody conjugates (ISACs)—that activate the immune system directly in tumors. This graph reflects analysts' expectations for the success of clinical trials of this innovative platform.
%20sales%20of%20the%20company%20Bolt%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bolt-Biotherapeutics&v=1772638857764 "Schedule of future (projected) sales of the company Bolt Biotherapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Bolt Biotherapeutics is developing "immune-stimulating antibody conjugates" (ISACs) for cancer treatment. This chart highlights expectations for the immune-pharma sector. It illustrates the search for new technological platforms capable of effectively activating the immune system to fight tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772638857833 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Bolt Biotherapeutics, Inc. is an immuno-oncology company developing a new class of drugs that activate innate and adaptive immunity to fight cancer. Its future depends on the success of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital for funding advanced and complex biotech platforms like Bolt's.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772638857848 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bolt Biotherapeutics
Bolt Biotherapeutics is developing a new class of immuno-oncology drugs that activate innate immunity to fight cancer. The chart shows the company's financial status at the clinical trial stage. Negative values represent investments in this cutting-edge scientific platform.
Market segment marginality - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs that activate the immune system directly in tumors. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in their sector, illustrating the financial potential if their technology is successful and commercialized.
Market marginality as a whole
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing a new class of drugs that stimulate innate immunity to fight cancer. This overall market profitability curve is irrelevant to the company. Its potential lies in the creation of breakthrough technologies. Success will be determined by clinical results.
Employees in the company, segment and market as a whole
Number of employees in the company Bolt Biotherapeutics
Bolt Biotherapeutics is an immuno-oncology company developing a new class of drugs that harness the innate and adaptive immune systems to fight cancer. This graphic shows the team of scientists advancing this complex technology through clinical trials.
Share of the company's employees Bolt Biotherapeutics within the market segment - Pharma immune
Bolt Biotherapeutics is creating a new class of immuno-oncology by harnessing the innate and adaptive immune systems to fight cancer. This chart shows the percentage of leading immunologists and antibody researchers the company has recruited in this cutting-edge field. It reflects its concentration of unique scientific talent to develop next-generation therapeutics.
Number of employees in the market segment - Pharma immune
Bolt Biotherapeutics is another company working at the forefront of immuno-oncology. It creates "immune stimulators" that activate innate and adaptive immunity to fight cancer. This graph illustrates how competitive and innovative this field is, with dozens of companies attracting the best minds to develop therapies of the future.
Number of employees in the market as a whole
Bolt Biotherapeutics is another player in the crowded but vital field of immuno-oncology. The high concentration of companies in this field creates a competitive environment that accelerates progress. This total employment chart reflects the thousands of scientists working at these companies, collectively bringing us closer to effective cancer treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics is a biotech company developing immunotherapy (ISAC) for cancer treatment. This chart represents the net intellectual capital valuation. The company's value is based on market expectations for its unique scientific platform. The chart shows how highly the market values this scientific potential and development pipeline per scientist.
%20of%20the%20company%20Bolt%20Biotherapeutics%20(BOLT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bolt-Biotherapeutics-BOLT&v=1772638858082 "Chart of market capitalization per employee (in thousands of dollars) of the company Bolt Biotherapeutics (BOLT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Bolt Biotherapeutics is another immuno-oncology company. It is developing a new class of drugs that stimulate the immune system to fight cancer. The chart shows how the market values their unique scientific approach and team. A high score may indicate investor confidence in the breakthrough potential of their platform.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772638858102 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Bolt Biotherapeutics is a biopharmaceutical company developing a new class of immuno-oncology drugs. This chart reflects the market's perceived value per employee, highlighting the company's high appreciation for cutting-edge scientific approaches in the fight against cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772638858108 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics is a clinical-stage biotech company focused on immuno-oncology. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns per scientist.
%20Chart%20Bolt%20Biotherapeutics%20(BOLT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bolt-Biotherapeutics-BOLT&v=1772638858117 "Company Profit Per Employee (in thousands of dollars) Chart Bolt Biotherapeutics (BOLT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing drugs that combine the precision of antibodies with the power of the immune system. Its core business is cutting-edge scientific research. The negative profit per employee, likely shown in this chart, is typical for biotech companies in clinical trials and reflects the high costs of maintaining a research team.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772638858132 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Bolt Biotherapeutics (BOLT) is a clinical-stage biotech developing ISACs (Boltbody), a new class of immunotherapy that "trains" the immune system to attack cancer. This is an R&D business. This chart shows the average profitability per employee across the market. For BOLT (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772638858139 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics is a clinical-stage immuno-oncology company. This chart reflects the company's path to commercialization. The current low values are typical for biotech companies in the R&D phase, but they could rise sharply if clinical trials are successful and the drug is brought to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bolt-Biotherapeutics-BOLT&v=1772638858148 "Sales chart per company employee Bolt Biotherapeutics (BOLT)")
Sales per employee in the market segment - Pharma immune
Bolt Biotherapeutics is a biotech company developing immuno-oncology (ISAC) drugs. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Bolt's scientific team.
Sales per employee for the market as a whole
Bolt Biotherapeutics is a clinical-stage biotech company developing immunotherapy (based on immune "stimulants") for the treatment of cancer. The company has no commercial revenue, which is irrelevant. Its entire value lies in the potential of its R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics is an oncology company developing "immune-boosting antibodies." This technology is complex and risky. This chart shows the odds on their clinical trials failing. The bears believe their drugs will be too toxic or insufficiently effective, a common fate for biotech companies.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bolt-Biotherapeutics-BOLT&v=1772638858205 "Short Shares Chart for the Company Bolt Biotherapeutics (BOLT)")
Shares shorted by market segment - Pharma immune
Bolt Biotherapeutics is an immuno-oncology company developing "immune stimulators" (ISACs) designed to help the immune system recognize and attack "cold" tumors. This chart reflects the total short position in the immuno-oncology sector. High values indicate general investor skepticism about the success of clinical trials of new, unproven immune technologies.
Shares shorted by the overall market
Bolt Biotherapeutics is developing "immunostimulating antibody complexes" for cancer treatment. It's a cutting-edge but complex immunotherapy. This chart reflects general fear. When investors are afraid, they're unwilling to bet on complex scientific platforms. They sell off BOLT shares, fearing the technology won't prove effective or that the company will run out of cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics is a biotech company developing "immunostimulating antibody conjugates" (Boltbodies) for cancer treatment. This is a complex immunotherapy. This oscillator measures the market's "temperature," showing when stocks are "overheated" (above 70) in anticipation of a breakout or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bolt-Biotherapeutics-BOLT&v=1772638858261 "RSI 14 indicator chart for the company's stock Bolt Biotherapeutics (BOLT)")
RSI 14 Market Segment - Pharma immune
Bolt Biotherapeutics is an oncology company developing "immunostimulating antibody complexes" (ISACs). This technology combines antibodies with immune system activators. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Bolt Biotherapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BOLT (Bolt Biotherapeutics)
Bolt Biotherapeutics is developing immunostimulatory antibody-drug conjugates (ISACs), a novel cancer immunotherapy platform. This chart shows the average analyst forecast. Their targets are based on early clinical data, progress in partnerships (such as with Genmab), and the potential of their Boltbody platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BOLT-Bolt-Biotherapeutics&v=1772638858298 "A chart showing analyst consensus forecasts for the expected stock price. BOLT (Bolt Biotherapeutics)")
The difference between the consensus estimate and the actual stock price BOLT (Bolt Biotherapeutics)
Bolt Biotherapeutics is an immuno-oncology company developing "stimulating" antibodies (the ISAC platform) that stimulate the immune system to attack cancer. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex yet cutting-edge scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BOLT-Bolt-Biotherapeutics&v=1772638858356 "A chart showing the difference between the consensus forecast and the actual stock price. BOLT (Bolt Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Bolt Biotherapeutics is a biotech company developing "immune stimulators" (the Boltbody platform) that "awaken" the immune system to attack cancer. This chart shows analysts' overall expectations for the entire immune pharma sector. It reflects whether experts believe in new R&D breakthroughs in oncology.
Analysts' consensus forecast for the overall market share price
Bolt Biotherapeutics (BOLT) is a biopharmaceutical company working at the forefront of immuno-oncology. They are developing "immune stimulators" designed to "awaken" the immune system within tumors. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bolt Biotherapeutics
Bolt Biotherapeutics is a bispecific biotech. Their Boltbody™ (ISAC) platform is a smart bomb: it combines an antibody (which finds cancer) with an immune activator (which stimulates the first line of defense) directly into the tumor. This graph is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and the market's confidence in their unique immunological approach.
AKIMA Market Segment Index - Pharma immune
Bolt Biotherapeutics (BOLT) develops weaponized antibodies (ISAC). Their Boltbody platform not only delivers the drug to the tumor but also simultaneously engages the innate immune system (macrophages) to attack the cancer. This chart shows the average index for the segment. It helps assess how this complex dual attack compares to the sector average.
The AKIM Index for the overall market
Bolt Biotherapeutics is an immuno-oncology company developing immune-stimulating antibody conjugates (ISACs). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this platform after clinical challenges.
